Clinical Data

About the inFoods IBS® Clinical Study

In a Prospective, Multi-Center, Double-Blind, Placebo-Controlled Study,
an inFoods® IBS elimination diet demonstrated a remarkable and statistically significant reduction in IBS symptoms over an 8-week period

  • Study Sites: Mayo Clinic, Harvard Beth-Israel, University of Michigan, University of Texas Houston
  • Study Design: 8-week, prospective, multi-center, double-blinded, placebo-controlled, randomized
  • Treatment Arm: True Diet - Elimination of positive foods (elevated levels of IgG) from the diet of IBS patients
  • Placebo Arm: Sham Diet – Elimination of non-positive foods (normal levels of IgG) from the diet of IBS patients

 

Endpoint Determination Study for An Antibody Guided Dietary Restriction Trial Using Biomerica inFoods® IBS Test in Patients With a Previous Diagnosis of Irritable Bowel Syndrome (IBS) (NCT03459482)

Investigators

William Chey, MD, AGAF, FACG, FACP

Principal Investigator

University of Michigan – Ann Arbor
Director of the Digestive Diseases Center
Co-Author of ACG Guidelines

Anthony Lembo, MD, FACG

Principal Investigator

Harvard - Beth Israel Deaconess Medical Center
Director, Center for GI Motility and Functional Bowel Disorders

Tisha Lunsford, MD

 

Mayo Clinic
Director of the Motility Interest Group

Brian Lacy, MD, PhD, FACG

Mayo Clinic
Former Co-Editor in Chief of the American Journal of Gastroenterology
Co-Author of ACG Guidelines

Eamonn Quigley, MD, MACG

Chief, Division of Gastroenterology and Hepatology at Houston Methodist

Brooks Cash, MD, AGAF, FACG, FACP, FASGE

University of Texas Health Science Center at Houston,
Chief of Gastroenterology

What if the results from a simple blood test could decipher which foods trigger IBS symptoms?

guide-icon
inFoods & IBS
click here
doctor-icon
For Physicians
click here
patient-icon
For Patients
click here
contact-icon
Clinical Data
click here